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Background: Understanding the quantitative relationship between a drug’s physical chemical properties and its
rate of intestinal absorption (QSAR) is critical for selecting candidate drugs. Because of limited experimental human
small intestinal permeability data, approximate surrogates such as the fraction absorbed or Caco-2 permeability are
used, both of which have limitations.
Methods: Given the blood concentration following an oral and intravenous dose, the time course of intestinal
absorption in humans was determined by deconvolution and related to the intestinal permeability by the use of
a new 3 parameter model function (“Averaged Model” (AM)). The theoretical validity of this AM model was
evaluated by comparing it to the standard diffusion-convection model (DC). This analysis was applied to 90
drugs using previously published data. Only drugs that were administered in oral solution form to fasting
subjects were considered so that the rate of gastric emptying was approximately known. All the calculations are
carried out using the freely available routine PKQuest Java (www.pkquest.com) which has an easy to use, simple
interface.
Results: Theoretically, the AM permeability provides an accurate estimate of the intestinal DC permeability for
solutes whose absorption ranges from 1% to 99%. The experimental human AM permeabilities determined by
deconvolution are similar to those determined by direct human jejunal perfusion. The small intestinal pH
varies with position and the results are interpreted in terms of the pH dependent octanol partition. The
permeability versus partition relations are presented separately for the uncharged, basic, acidic and charged
solutes. The small uncharged solutes caffeine, acetaminophen and antipyrine have very high permeabilities
(about 20 x 10-4 cm/sec) corresponding to an unstirred layer of only 45 μm. The weak acid aspirin also has a
large AM permeability despite its low octanol partition at pH 7.4, suggesting that it is nearly completely
absorbed in the first part of the intestine where the pH is about 5.4.
Conclusions: The AM deconvolution method provides an accurate estimate of the human intestinal
permeability. The results for these 90 drugs should provide a useful benchmark for evaluating QSAR models.Background
Despite the multitude of publications describing the differ-
ent factors that affect the rate of intestinal absorption of
drugs, there is only limited experimental data for the hu-
man small intestinal permeability of the thousands of
drugs that are orally absorbed. The quantitative structure
activity relationship (QSAR) between a drug’s physical
chemical properties and its rate of intestinal absorption is
obviously of great importance in selecting candidateCorrespondence: levit001@umn.edu
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reproduction in any medium, provided the ordrugs. The standard approach is to relate some property
of the drug (e.g. octanol/water partition, Caco-2 cell per-
meability, etc.) to the fraction absorbed in humans [1,2].
Although the fraction absorbed is a useful clinical param-
eter [3], it is a crude measure of permeability. Since most
successful drugs are nearly 100% absorbed, they cannot
provide any quantitative data about their relative perme-
ability. Furthermore, the fraction absorbed may be
influenced in uncertain ways by factors such as intestinal
metabolism or large intestinal absorption.
More recently, there have been direct measurements
of human small intestinal permeability using the regional
perfusion technique. In a recent communication, Dahan,is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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why these measurement of “…jejunal permeability
(alone) may not always adequately predict” the fraction
absorbed. This includes small intestinal heterogeneity (such
as variations in pH and membrane transport systems) and
large intestinal absorption. In addition, the regional perfu-
sion conditions used in these measurements may differ
from the normal physiological conditions. For example, the
high pressure and volume in the perfusion system may in-
crease access to the intervillous space allowing increased
paracellular transport of PEG markers [5].
This paper describes a new approach to measuring hu-
man intestinal permeability during normal drug absorp-
tion. It is well recognized that the time course of
intestinal absorption can be determined from deconvo-
lution of the plasma concentrations following oral and
intravenous input in the same subject. There are a var-
iety of mathematical approaches to this deconvolution
[6]. Some care is required in this procedure because ran-
dom errors in the plasma concentration data can lead to
non-physiological fluctuations or negative values in the
predicted absorption rate. The simplest procedures as-
sume that the absorption can be described by some sim-
ple function (e.g. 3 parameter gamma [6] or Hill
function [7]) which is then adjusted to give the best fit
to the oral plasma absorption curve. More sophisticated
approaches use generalized functions with varying num-
bers of parameters [8,9]. This absorption function must
then be interpreted in terms of the intestinal permeabil-
ity. This is difficult because intestinal transit, dispersion
and absorption is complicated and poorly understood.
The most widely used quantitative model of intestinal
absorption is the “compartmental absorption and tran-
sit” (CAT) model which has been incorporated into the
commercial program GastroPlus™ [10,11]. This CAT
model describes the small intestine in terms of 7 sequen-
tial well mixed compartments with passive absorption
(determined by the permeability) and one way transport
in the aboral direction. Because the solution of this
model’s equations requires numerical calculations and
does not have an analytical solution, it cannot be easily
adapted for the deconvolution approach.
In this paper a new 3 parameter function (“Averaged
Model” (AM)) that accurately mimics the transit, disper-
sion and absorption of the small intestine is used to de-
termine the intestinal permeability by deconvolution.
The range of validity of this AM model is evaluated by
comparing it with the more exact diffusion convection
model (DC). This AM procedure is then applied to pub-
lished data to determine the human intestinal permeabil-
ity of 90 drugs. The main criterion for the selection of
drugs for this analysis is that they were administered as
an oral solution in order to eliminate the ambiguity and
variability in the rate of gastric emptying.Methods
Numerical solution of the Diffusion-Convection (DC)
model equations
Ni et. al. [12] have described a model of intestinal tran-
sit which combines convection, dispersion and absorp-
tion (DC model). The main assumption is that there is
an equal volume flow into and out of each intestinal
region so that the cross-sectional area (radius = r) and
the convective flow (F) remains constant as the solute
spreads along the intestine by convection and disper-












The left hand side is the time dependent change in
the concentration c(x,t) (where x is the distance from
the pyloric sphincter). The first term on the right is the
dispersive mixing, the second is the convective flow
and the third is the absorption term where r is the
intestinal radius (cm), D is the dispersion coefficient
(cm2/sec), F is the volume flow (cm3/sec) and P is the
permeability (cm/sec).
Ni et. al. [12] derived an exact analytical solution to
Equation (1) that assumes as a boundary condition an
exponential concentration at x = 0. This condition is not
physiological because it implies that, in addition to the
convective flux out of the stomach, there is also a non-
physiological dispersive flux both out of and into the
stomach (and out of and into the large intestine). For
this reason the analytical solution will not be used here
and, instead, a finite difference numerical approxima-
tion to Equation (1) will be used in which there is only
a convective flux from the stomach to the small intes-
tine and from the small intestine to the large intestine.
(Also, the numerical solution is computationally much
faster than the analytical solution). The small intestine
is divided into N equal sections with the following dif-
ference equations:
i ¼ 1 : ΔV dc 1½ 
dt
¼ IG tð Þ− F þ ΔP þ Deð Þc 1½  þ Dec 2½ 
0 < i < N : ΔV
dc i½ 
dt
¼ F þ Deð Þc i−1½ − F þ ΔP þ 2Deð Þc i½ 
þ Dec iþ 1½ 
i ¼ N : ΔV dc N½ 
dt
¼ F þ Deð Þc N−1½ − F þ Deþ ΔPð Þ c N½ 
ð2Þ
where c[i] is the concentration in the ith compartment
at time t, IG(t) is the rate of gastric emptying into the
intestine, r = intestinal radius, L = intestinal length,
S = surface area = 2πrL, V = volume = πr2L, ΔP = PS/N,
ΔV = V/N and De = πr2DN/L. The rate EDC(t) that the
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the large intestine is:
EDC tð Þ ¼ F c N½  ð3Þ
The cumulative amount ADC(ti) that has entered the
large intestine at time ti = i Δt is:
ADC tið Þ ¼ ∑ij¼1 EDC tj
 
Δt ð4Þ
The absorption rate RDC(t) at time ti is:
RDC tið Þ ¼ ΔP∑Ni¼1c i½  ð5Þ
Gastric emptying in humans of non-caloric fluids is ap-
proximately exponential with a half time of about 15 minutes
[13,14] and it will be assumed that IG(t) is exponential:
IG tð Þ ¼ FC0 exp −t=TGð Þ ð6Þ
where TG is the time constant for gastric emptying, C0 is
the gastric concentration at t = 0 and FC0 =Dose/TG. In
addition, the parameters D, F and P will be described in
terms of 3 other time constants:
TP ¼ r= 2Pð Þ TF ¼ V=F TD ¼ L2= 2Dð Þ
ð7Þ
Equation (2) is solved numerically using N= 50 and the
Rosenbrock method as implemented in Maple (Maplesoft™).
Some of the figures shown here are Maple plots.
Derivation and description of the “Averaged Model (AM)”
The DC equation (Equation (1)) has the interesting prop-
erty that, if the drug is completely absorbed in the small
intestine and the amount entering the large intestine can
be neglected, it has the same kinetics as a well stirred
compartment. This can be seen by integrating Equation





¼ I0 tð Þ −IL tð Þ −2πrLPC
C ¼ 1=Lð Þ
ZL
0
c x; tð Þdx I0 tð Þ ¼ −πr2Ddc 0; tð Þdx þ Fc 0; tð Þ
IL tð Þ ¼ −πr2Ddc L; tð Þdx þ Fc L; tð Þ
ð8Þ
where C is the average intestinal concentration and I0(t)
and IL(t) are the inflow and outflow rates. If the outflow




¼ I0 tð Þ−PSC ð9Þ
This is identical to the case of a well mixed compart-
ment of volume V with arbitrary input I0(t). Assuming
that I0(t) = IG(t) (Equation (6)) and solving thedifferential Equation (9) one obtains the “averaged
model” (AM) equation for the case of 100% absorption:
C tð Þ ¼ Dose=Vð Þ TP exp −t=TGð Þ − exp −t=TPð Þ½ = TG−TPð Þ
ð10Þ
where TP and TG are the permeability and gastric
emptying time constants (Equation (6) and (7)). The rate
of absorption (R(t)) from the small intestine is:
R tð Þ ¼ PSC tð Þ ¼ Dose exp −t=TGð Þ − exp −t=TPð Þ½ = TG−TPð Þ
ð11Þ
This AM R(t) is identical to the absorption rate for the
DC model for the case where all the solute is absorbed
(IL(t) = 0, Equation (8)). It should be emphasized that al-
though Equation (9) is similar to the well-mixed equa-
tion it is not physically equivalent because C is the
average concentration and it is not assumed that the in-
testine is well mixed. For example, it would be erroneous
to assume that the rate of solute flow into the large in-
testine was equal to F*C.
As discussed above, Equation (11) is a rigorously accur-
ate description of the intestinal absorption for the DC
model only for the case where all of the solute is absorbed
in the small intestine. This result can be generalized to the
arbitrary permeability case where only a fraction FA of the
total Dose is absorbed in the small intestine:
RM tð Þ ¼ M exp −t=TGð Þ − exp −t=TPð Þ½ = TG−TPð Þ
M ¼ FADose
ð12Þ
where M is the total amount absorbed. In addition, the re-
lationship between TP and P must be modified for this
general case. The C in Equation (8) is based on the as-
sumption of 100% absorption. If, for example, only 50%
were absorbed the actual concentration would be twice
this value of C and the value of P would be reduced by
half. Thus, the general relationship between TP and the
averaged model intestinal permeability (PM) is:
PM ¼ FA P ¼ FA r= 2TPð Þ ð13Þ
The amount absorbed (AM(t)) as a function of time is:
AM tð Þ ¼
Z t
0
RM τð Þdt ¼ Mf1þ ½TP exp −t=TPð Þ
−TG exp −t=TGð Þ = TG−TPð Þg
ð14Þ
These AM model expressions for the intestinal absorp-
tion rate RM(t) and PM are only approximations to the
exact DC model for this general case where not all the
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roximation will be evaluated by comparing it to the
DC model for a range of experimental parameters
(see Results, Comparison of DC and AM models).
RM and M represent the rate and total amount
absorbed across the small intestinal epithelial luminal
membrane. Assuming a linear system, the rate of solute
entering the systemic circulation (RSM) is:
RSM tð Þ ¼ MS exp −t=TGð Þ − exp −t=TPð Þ½ = TG−TPð Þ
MS ¼ FA 1−EHð Þ 1−EIð ÞDose ð15Þ
where EH and EI are the hepatic and intestinal extraction
ratios [15]. The hepatic extraction (EH) can be estimated
from the liver blood flow (QH) [15] and the whole blood
liver clearance (ClH):
EH ¼ ClH=QH ð16Þ
The liver clearance (ClH) was estimated by correcting the
whole blood clearance following the IV infusion for the
fractional renal clearance using data obtained in the same
subjects that were used for the permeability estimates.
Equation (15) is a simple 3 parameter function whose
parameters (MS, TG and TP) can be determined experi-
mentally by deconvolution (see below for details) of the
blood concentration time course following IV and oral
doses. The fraction absorbed (FA) can be determined
from MS and estimates of EH and EI (Equation (15)). Fi-
nally, the AM model intestinal permeability (PM) can be
determined from FA and TP (Equation (13)).
Equation (15) is symmetrical in TG and TP so that
there is an ambiguity in distinguishing the gastric
emptying time constant TG from the permeability time
constant TP. Most of the applications described here will
be based on data obtained using oral solutions (not tab-
lets) given to fasting subjects and the time constant that
is closest to 10 to 15 minutes will be assumed to be TG .
The theoretical accuracy of the AM model absorption
rate RM (Equation 12) was evaluated by comparing it with
the exact DC model RDC (Equation 5). A set of the 7 DC
parameters (Dose, TG, TP, TF, TD, r, L) were selected and
the DC model intestinal absorption rate and fraction
absorbed was determined. Then, the AM model parame-
ters (M, TG, TP, Equation (12)) that provided the best fit to
the DC absorption rate were determined by minimizing
the following error function using the optimization routine
in Maple (Maplesoft™):
Error ¼ 1=Nð Þ∑Ni¼1 RDC i½ −RM tið Þð Þ2 ð17Þ
where ti = i Δt and comparing the AM model parameters
(FA, TP and TG) with the actual input DC parameters.Experimental determination of the averaged model (AM)
parameters by deconvolution
The determination of the 3 AM model parameters (MS,
TG and TP) is based on standard procedures that have
been described previously [6]. First, the 2 or 3 exponen-
tial systemic bolus response function r(t) is determined
from the experimental blood concentration time course
following the known IV infusion. The blood concentra-
tion Coral(t) following the oral dose is equal to the con-
volution of r(t) and the AM model systemic absorption
rate RSM(t) (Equation (15)):
Coral tð Þ ¼
Z t
0
r t−τð ÞRSM τð Þdτ ð18Þ
The 3 AM model parameters (MS, TG and TP) are
then estimated by finding the parameter set that mini-




Coral tkð Þ−Ckj j
Ck þ noise ð19Þ
where Ck is the experimental blood concentration at
time tk following the oral dose. The “noise” determines
the relative weighting of each data point and can be ar-
bitrarily adjusted but is usually set to 10% of the average
blood value. The optimized set of parameters is deter-
mined by a non-linear Powell minimization routine [16].
Most of the drugs were administered as oral solutions in
fasting subjects and TG was forced to be in the range of
10 to 20 minutes (the normal range for non-caloric
fluids [13,14]) and only the two parameters TP and MS
were freely adjusted. For a few solutes that were admin-
istered as capsules or tablets, all 3 parameters were
adjusted.
These procedures have been implemented in PKQuest
Java, a freely distributed software program that has been
used previously for pharmacokinetic analysis of more than
30 different solutes in a series of publications [7]. The im-
plementation is designed to be user friendly and simple to
use. The user only needs to enter 1) the dose and duration
of the constant IV infusion; 2) the experimental blood
concentration for the IV dose (which can be copied and
pasted from a standard Excel file); and 3) the experimental
blood concentration following the oral dose. The program
then finds the optimum set of AM parameters. It also out-
puts 4 plots that are useful for evaluating the results: 1) A
comparison of the experimental blood concentration for
the IV dose versus the blood concentration predicted by
bolus response function (there is usually nearly perfect
agreement). 2) The AM model absorption rate as a func-
tion of time; 3) AM total absorption as a function of time;
and 4) a comparison of the experimental blood concen-
tration following the oral dose versus the AM model
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ful because it provides the best measure of the quality of
the AM model. See Figures 1, 2, 3 and 4 for examples of
these plots. PKQuest Java and a detailed tutorial can be
freely downloaded from www.pkquest.com. Also available
for download are the complete data sets for the 90 solutesB
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Figure 1 AM model deconvolution solution for intestinal
absorption of acetaminophen. Figure 1A shows a comparison of
the experimental blood concentration data points (red circles)
following an IV input versus the theoretical blood concentration
determined from the 2 exponential systemic response function
(line). Figure 1B shows a comparison of the experimental blood
concentration data points (red circles) following an oral input with
the theoretical blood concentration prediction determined from the
deconvolution solution of the AM absorption rate function.
Figure 1C shows the cumulative AM absorption amount as a
function of time.
Figure 2 AM model deconvolution solution for intestinal
absorption of risedronate. See Figure 1 for details.discussed in this paper. This allows the user to reproduce
all of the results.
Experimental intestinal absorption data
In order to be a candidate for determination of intestinal
permeability it was required that the solute met the following
4 conditions: 1) intravenous and oral dose pharmacokinetics
in the same subject; 2) the oral dose was in the form of a so-
lution (not tablet) to fasting subjects; 3) the drug’s pharma-
cokinetics are linear, at least in the concentration range that
is investigated; 4) the drug is soluble at the concentrations
used in the absorption study. These conditions severely limit
the number of experimental results that can be used. Condi-
tion #1 is satisfied in only a small fraction of permeability
studies. Condition #2 also severely restricts the number of
possible candidates because tablets or capsules are used in
most oral drug studies. A thorough search of the published



















































Figure 3 AM model deconvolution solution for intestinal
absorption of cimetidine. Figure 3A shows a comparison of the
experimental blood concentration data points (red circles) following
an oral input versus the theoretical blood concentration prediction
determined from the deconvolution solution of the AM absorption
rate function. Figure 3B shows the cumulative AM absorption
amount as a function of time.































































Figure 4 AM model deconvolution solution for intestinal
absorption of acetylcysteine. Figure 4A shows a comparison of
the experimental blood concentration data points (red circles)
following an oral input versus the theoretical blood concentration
prediction determined from the deconvolution solution of the AM
absorption rate function. Figure 4B shows the cumulative AM
absorption amount as a function of time.
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drugs that were administered as tablets have been included
if the drug had a high water solubility so that the tablet
would be rapidly dissolved and a low permeability (long TP)
that could not be confused with the TG. The results and ana-
lyses are summarized in the Excel file that is included in the
Additional file 1: “Table 2”. Additional file 1: Table 2 lists the
solute, a link to the reference publication, the AM model pa-
rameters, a subjective measure of the quality of the AM fit
to the data and the calculated permeability. The table in-
cludes the ionization behavior of the solute (weak acid, base,
neutral or always ionized) in the pH range of 4 to 8 and the
pKa if it is a weak base or acid. Also listed is an estimate of
the experimental log(octanol/water) partition coefficient at
pH 7.4 (log D). For most solutes there are multiple reported
values of log D that can vary by as much a log unit. For
those solutes which are available on the LOGKOW site
maintained by James Sangster, the value listed is an approxi-
mate average of the listed values. When necessary, the log
Pow values were converted from pH1 to a different pH2using the following relations (this assumes that only the neu-
tral solute has a finite octanol partition) [17]:
Monoproticbase : logPow2 ¼ logPow1 þ log 1þ 10 pKa−pH1ð Þ
 
− log 1þ 10 pka−pH2ð Þ 
Monoproticacid : logPow2 ¼ logPow1 þ log 1þ 10 pH1−pKað Þ
 
− log 1þ 10 pH2−pKað Þ 
ð20Þ
The experimental perfused human jejunum permeabil-
ity [18] and the Caco-2 permeability are also listed in
Additional file 1: Table 2 if they were available. The form
of the oral dose (solution, tablet, capsule) is listed and
solutes which may have solubility limitations are marked
in the table. If there is suggestive evidence that the intes-
tinal absorption is protein mediated (either influx or ef-
flux), this is also indicated. The experimental data points
At = 100 min 
t = 20 min 
B
C
t = 300 min 
Figure 5 Diffusion convection concentration profile. The
diffusion convection model concentration as a function of distance
from the pyloric sphincter is shown at 20 (Figure 5A), 100 (B) and
300 minutes (C) after administering the oral dose as a bolus to the
stomach for an impermeable (P = 0) solute. The profile is shown for
4 different values of the dispersion time constant (TD): 2000 (red);
1000 (blue); 200 (green); and 20 minutes (black). For all profiles TF =
200 minutes; TG = 15 minutes; r = 1 cm; L = 600 cm and Dose = 1.
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(Silk Scientific Corporation).
Results
Solution and parameter study of the Diffusion-Convection
(DC) model
The DC model differential equation (Equation (2)) was
solved numerically. Figure 5A, B and C show the DC con-
centration profile for a non-permeable (ΔP = 0) solute at
time = 20, 100 and 300 minutes after the oral dose with TD
(dispersive transit time) values of 2000 (red curve), 1000
(blue), 200 (green) and 20 (black) minutes. Unless other-
wise stated, all of the plots described here have TG = 15
minutes (gastric emptying time constant), TF = 240 minutes
(convective small intestinal transit time), N = 50 (there
is no significant change in the results for greater N),
Δt = 1 minute, Dose = 1.0, r = 1 cm and L = 600 cm. Since
the concentration profile has a strong dependence on TD,
these plots could be used to estimate the value of TD
(and TF) in the human if experimental measurements of
the concentration profile along the small intestine for im-
permeable solutes were available. Unfortunately, no such
measurements have been reported for humans or other
large mammals (they have been made in rats [19]).
The experimental measurement in humans that can be
used to estimate TD is the distribution of small intestinal
transit times determined from the appearance of some non-
permeable label in the large intestine [20]. Figure 6 shows
the DC cumulative amount entering the large intestine as a
function of time (Equation (4)) for TD = 2000 (red), 1000Figure 6 Diffusion convection small intestinal transit time. The
diffusion convection amount leaving the small intestine and
entering the large intestine as a function of time for an
impermeable solute. Same conditions as for Figure 5.
AP = 4.17 x 10-4 cm/sec 
TD = 200 min 
DC Model 
AM Model 
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ditions as in Figure 5. The shape of the curves can be
roughly characterized by the time of first appearance of sol-
ute and the half time. Caride et. al. [21] reported the time of
arrival (time at which a “sustained” increase in breath hydro-
gen or 99mtechnetium-diethylenetriaminepentaacetic acid
was first detected) of about 73 minutes. Based on an exten-
sive literature review, Davis et. al. [22] found an average
small intestinal half time of about 240 minutes. From
Figure 6, a TD of about 200 minutes provides the best fit to
these experimental measurements in humans.
In the next section, the DC model will be used to
evaluate the accuracy of the AM model approximation.
The plots in Figures 5 and 6 are for non-permeable sol-
utes. Figure 7 shows a plot of the DC fraction absorbed
versus the permeability (10-4 cm/sec) for TD = 1000
(blue) and 200 (green) minutes. It can be seen that for
the high permeability solutes the fraction absorbed in-
creases by about 5% as TD increases 5 fold (i.e. as the
dispersion rate decreases). This produces a small de-
pendence of the error in the AM absorption rate on TD
(see below) which is quantitated in the next section.
Comparison of DC and AM models – theoretical
evaluation of accuracy of AM model approximation
The procedure that will be used to measure the experi-
mental permeability is to fit the AM absorption rate
Equation (15) to the systemic absorption rate determinedFigure 7 Permeability dependence of the diffusion
convection intestinal absorption. The fractional absorption of
the diffusion convection model as a function of the permeability
in units of 10-4 cm/sec for a dispersion time constant (TD) of 1000
(blue) or 200 minutes (green). The rest of the conditions are the
same as in Figure 5.by deconvolution. The accuracy of this procedure will be
theoretically tested here by fitting Equation 15 to the gen-
eral DC model absorption rate and comparing the AM
permeability to the permeability that is used to generate
the DC absorption data. Figure 8A and B compare the ab-
sorption rate as a function of time for the DC model (red)
versus the best fit AM model (blue) for the case where the
DC TD = 200 minutes and TF = 240 minutes (and TG =B
P = 0.00417 x 10-4 cm/sec 
TD = 200 min 
Figure 8 Comparison of intestinal absorption rate for DC and
AM models with TD = 200 minutes. The DC model rate of
absorption (red) was generated for a high permeability solute (P =
4.17 x 10-4 cm/sec, Figure 8A) and a low permeability solute (P =
0.00417 x 10-4 cm/sec, Figure 8B) with the rest of conditions the
same as in Figure 5. Then the AM model parameters that provided
the best fit to the DC model were determined and the AM
absorption rate (blue) plotted. See Table 1 for tabulation of the
AM parameters.
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AM model provides a nearly perfect fit to the DC absorp-
tion rate for the case of a relatively high permeability solute
(TP = 200 min, corresponding to P = 4.167 × 10
-4 cm/sec).
This is expected because only 1% of the solute passes
from the small to large intestine for this high perme-
ability and, as shown above, the AM and DC models are
theoretically identical if all the solute is absorbed. More
surprisingly, the DC and AM models are nearly identical
(Figure 8B) even for solutes with a very low permeability
(P = 0.004167 × 10-4 cm/sec) where only 1% of the solute is
absorbed. If the dispersion time constant (TD) is increased
to 1000 minutes, the AM model provides a poorer approxi-
mation to the DC absorption rate for solutes with a low
permeability (Figure 9B).A
P = 4.17 x 10-4 cm/sec 




P = 0.00417 x 10-4 cm/sec 
TD = 1000 min 
Figure 9 Comparison of intestinal absorption rate for DC and
AM models with TD = 1000 minutes. See Figure 8 for details.The quantitative comparison between the DC pa-
rameters used to generate the absorption rate and the
AM parameters (TG, TP, and FA) that provide an opti-
mal fit to this DC absorption rate are listed in Table 1
for a large range of values of the DC parameters. For
TD = 200 min, the AM permeability is within 20% of
the DC permeability for a thousand fold permeability
range (total absorption varying from 1% to 99%). For
TD =1000 min, the AM permeability can reach values
60% greater than the DC permeability for very low per-
meability solutes. Since the normal human TD is about
200 minutes (Results, previous section), these results
show that the AM model provides a good approxi-
mation to the exact DC model for a wide range of
permeabilities.
AM model estimates of the human intestinal permeability
of 90 solutes
The Excel Table in the Additional file 1: Table 2 lists the
values of the intestinal permeability for 90 solutes deter-
mined using the AM model and deconvolution. As
discussed in the Methods there are two time constants
in the AM model. For most of the solutes in this table,
an oral solution was administered to fasting subjects so
that the value of T in the range of 10 to 20 minutes can
be assumed to be TG. For the few solutes in the table in
which a tablet or capsule was administered, the solute
had such a low permeability that it was clear that the
longer T must correspond to TP.
In order to determine the permeability it is essential to
relate the rate of solute absorption into the systemic cir-
culation determined by deconvolution to the rate of in-
testinal absorption and this requires estimates of the
liver and intestinal first pass extraction (Equation (15)).
The liver extraction was determined from the estimated
liver blood flow and the liver clearance (Equation (16)).
The liver clearance is equal to the total systemic clear-
ance (determined from the IV input blood data)
corrected for the fractional renal clearance. These values
are listed in Additional file 1: Table 2 for each solute.
The value for the liver flow is just an estimate and for some
drugs, e.g. β-blockers, the value is reduced. The intestinal
extraction is more uncertain. Although certain drug classes
are known to have significant intestinal metabolism,
there is no quantitative data available in humans [23].
In Additional file 1: Table 2 the column labeled “Est Frac-
tion Absorbed” represents the final estimate taking ac-
count of the best guess for intestinal extraction.
Three representative examples of AM model deconvo-
lution calculations will be described in detail. Acet-
aminophen is the classic example of a high permeability
drug. Its intestinal absorption rate is usually assumed to
be so fast that its absorption rate is a measure of the rate
limiting gastric emptying [24-26]. The deconvolution
Table 1 Comparison of “averaged” (AM) and dispersion convection (DC) absorption rates
DC Model AM Model
PDC (10
-4 cm/sec) TD (min) TG (min) Fr. Absorb PAM (10
-4 cm/sec) TG (min) Fr. Absorb
4.167 200 15 .987 4.77 17.2 .989
0.4167 200 15 0.600 0.493 18.56 0.604
0.04167 200 15 0.109 0.0514 19.76 0.111
0.004167 200 15 0.0119 0.00517 19.9 .012
4.167 1000 15 0.999 4.167 15 0.999
0.4167 1000 15 0.658 0.522 20.8 0.690
0.04167 1000 15 0.111 0.0645 29 0.121
0.004167 1000 15 0.0119 0.0067 30 0.0129
4.167 200 60 0.997 4.155 60.0 0.997
0.04167 200 60 0.109 0.062 86 0.107
4.167 1000 60 0.999 4.167 60.0 0.999
0.04167 1000 60 0.112 0.0879 114.5 0.121
The theoretical time dependent absorption rate was generated for the DC parameters listed in the table (PDC = permeability, TD and TG = the dispersion and
gastric emptying time constants). For all results, TF = 240 min, r = 1 cm, L = 700 cm. The DC “Fr. Absorb” is the resultant cumulative fraction absorbed. The AM
parameters (permeability (PAM), TG and Fr. Absorb) were then adjusted to obtain the optimum fit to the DC absorption rate, similar to the procedure used to
determine the experimental human small intestinal permeability by deconvolution.
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Ameer et. al. [27] for a 650 mg IV and oral (elixir) dose
(data for one “representative” subject). Figure 1A shows
the 2 exponential response function fit to the IV input
data. Figure 1B compares the AM model prediction of
the blood concentration with the experimental data for
the oral dose, and Figure 1C shows the cumulative pre-
dicted absorption rate. The AM parameters are M =
545 mg, and the two time constants are 2 and 14 mi-
nutes. As discussed above, it is assumed that the time
constant closest to 15 minutes is TG, and therefore TP =
2 minutes. Correcting M for the liver extraction (Equation
(16)) yields a fraction absorbed of 1.07; i.e. 100% absorp-
tion which is expected given the fact that the amount
absorbed reaches its maximum by 50 minutes (Figure 1C),
well before one would expect a significant amount to pass
into the large intestine. From Equation (13), assuming an r
of 1 cm, the acetaminophen permeability PM is 41.7 × 10
-4
cm/sec. There are two other published sets of acetamino-
phen data that can be used to estimate the permeability by
deconvolution. The data of Divoll et. al. [28] (650 mg oral
elixir data for representative “elderly” subject) has a PM of
54 × 10-4 and that of Eandi et. al. [29] (averaged data
(n = 9) for 1 gm oral “drops”) has a PM of 12.6 × 10
-4 cm/sec.
Risedronate is a pyridinyl bisphosphonate with a very
low intestinal permeability (bioavailability < 1%). Despite
this low permeability, the plasma pharmacokinetics de-
scribed by Mitchell et. al. [30] after an oral (30 mg solu-
tion) and IV infusion (0.3 mg) can be used to determine
the time course of intestinal absorption by deconvolu-
tion (Figure 2). The AM model provides an excellent fit
to the oral plasma data (Figure 2B) with M = 220 mg(= 0.73% of 30 mg oral dose), TG = 14 and TP = 79.4 mi-
nutes. Using the fraction absorbed of 0.0073 in Equation
(13), PM = 0.008 × 10
-4 cm/sec. (Since risedronate is not
metabolized [30], there is no significant first pass meta-
bolism.) The absorption is complete by 300 minutes
(Figure 2C) presumably because this is the time required
for complete emptying into the large intestine. This result
also suggests that there is no significant absorption from
the large intestine.
First pass intestinal extraction cannot be quantita-
tively measured in humans. In Additional file 1: Table 2
the assumed intestinal metabolism is indicated by the dif-
ference between the estimated total absorption (the col-
umn labeled “Est Fract Abs Small Intestine”) and the
systemic absorption corrected for the liver extraction (col-
umn labeled “Fract Abs Corrected for Liver Clearance”).
For example, cimetidine has a highly variable bioavailabil-
ity of about 65% that has been attributed to either low
intestinal permeability or intestinal metabolism [31].
The AM model provides a good fit (Figure 3A) to the
blood concentration following a 300 mg oral solution
dose [32]. The AM parameters are M = 175 mg, TG =
10 and TP = 25 minutes. Correcting for liver extraction
raises the amount absorbed to 203 mg (68% of the oral
dose). From the AM model time course of the amount
absorbed (Figure 3B) it can be seen that the absorption is
complete by about 100 minutes. This is short compared to
the presumed small intestinal transit time of about 300 mi-
nutes, suggesting that permeability is not limiting and that
intestinal metabolism is responsible for the incomplete ab-
sorption. This approach of assuming that permeability is
not rate limiting if the absorption is completed in, e.g.,
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mining if intestinal metabolism is important. (Note: this
criteria is not applicable to acidic drugs, see Discussion).
The extreme example of this for the drugs in Additional
file 1: Table 2 is domperidone for which as much as 63%
may be cleared by intestinal metabolism [33]. Cimetidine
and domperidone are exceptions and for most of the
drugs in Additional file 1: Table 2 intestinal metabolism is
not significant.
Discussion
As shown above (Results, Comparison of DC and AM
models), the 3 parameter averaged model (AM) provides
a good estimate of the small intestinal permeability if the
following 2 conditions are met: 1) gastric emptying can
be described by a single exponential process; and 2) the
assumptions underlying the diffusion-convection (DC)
model are valid. In addition, to convert the AM value of TP
to an absolute permeability requires an assumption about
the small intestinal radius (r, Equation (13), assumed =
1 cm). The analysis listed in the Additional file 1: “Table 2”
is limited primarily to drugs that were administered as oral
solutions to fasting subjects, conditions for which the
exponential emptying should be a good approximation
[14]. The basic assumption of the DC model is that the
small intestine can be described by a uniform volume cy-
linder with convective flow into each segment exactly bal-
anced by flow out, combined with a mixing dispersion
term, with all properties uniform for its entire length. This
is, at best, an approximate description of the small intes-
tine. Little is known about the details of small intestinal
volume, mixing and dispersion in a fasting human subject
that has swallowed the small volume of water (about
200 ml) that is usually administered in these oral solution
dose studies.
Probably the most severe limitation of the DC model
is the assumption that the parameters do not vary over
the length of the intestine. The luminal pH definitely
varies with position and, since the permeability of weak
acids and bases depends critically on pH, this implies
that their permeability will also vary with position. There
have been a number of measurements of the pH position
dependence of the human intestine. In a review of the
older literature, Gray and Dressman [34] reported pH
values of 4.9 in proximal duodenum, 5.3 in terminal
duodenum, 4.4-6.5 in proximal jejunum, 6.6 in mid and
terminal jejunum and varying from 6.5 in proximal
ileum to 7.4 in terminal ileum. Using in situ pH micro-
electrodes Ovesen et. al. [35] simultaneously measured a
fasting pH of 2.05 in stomach, 3.03 in duodenal bulb, 4.9
in mid duodenum and 4.92 in proximal jejunum. Using
radiotelemetry capsules swallowed “with a small quantity
of water”, Evans et. al. [36] reported pH values of 6.63 in
jejunum, 7.41 in mid small bowel, 7.49 in ileum andfrom 6.37 to 7.04 in colon. Using the “smart pill”,
Lalezari [37] recently reported pH values varying from
5.6, 6.2, 6.68, 6.9 for proximal to terminal small intes-
tinal quartiles. Thus, the small intestinal pH can be as-
sumed to start at about 4.4 in an initial short segment of
the duodenum, increasing to 5.4 in the first part of the
jejunum, to 6.4 in mid intestine and to 7.4 in the ter-
minal ileum.
The results in Additional file 1: Table 2 will be
discussed in terms of the classical pH partition assump-
tion that the permeability is proportional to the concen-
tration of the neutral moiety, using the octanol/water
partition (log D) as representative of the epithelial mem-
brane partition and the pKa to estimate the neutral con-
centration [38]. Since the small intestinal pH varies from
about 4.4 to 7.4, this pH partition hypothesis implies
that the intestinal permeability can vary by as much as
1000 fold over its entire length. Although more compli-
cated approaches that combine log D with estimates of
polar surface area and hydrogen bond donors can im-
prove permeability estimates [39], log D captures the
main features and will be focused on here. It is hoped
that the data set in Additional file 1: Table 2 will be used
in future evaluations of these advanced models.
Since the permeability of the 18 uncharged solutes in
Additional file 1: Table 2 should not be affected by this
pH heterogeneity, one would predict that the AM per-
meability for these solutes should be a good approxima-
tion to the true permeability. Figure 10 shows a plot of
the log D versus the log of the permeability (cm/sec).
The 5 colored points indicate solutes for which there is
strong evidence of protein mediated transport. The 3
green points have P-glycloprotein mediated efflux (di-
goxin and β-methyl digoxon [40] and colchicine [41])
which should reduce their permeability. The blue point
is lamivudine which is a substrate for the organic cation
transporters [42] and the red point is xylose which has a
carrier mediated transport (probably the glucose trans-
port system) [43-45], both of which will increase the
“permeability”. The black line is the least squares regres-
sion fit to the black (non-protein mediated) points.
There is only a weak correlation between permeability
and log D. Presumably other factors besides simple
octanol partition are important. The 4 points with the
highest permeability (caffeine, acetaminophen, antipyrine
and cotinine) are all low molecular weight (< 200) sol-
utes. The 2 points with log D < −1.5 (acyclovir and gan-
ciclovir) may have significant paracellular transport.
One would predict that the small intestinal pH hetero-
geneity should significantly influence the apparent AM
“permeability” of the basic solutes listed in Additional
file 1: Table 2. Since the basic solutes have a higher un-
charged concentration at the higher pH, they will tend
to be absorbed in the terminal small intestine – delaying
Figure 10 Permeability versus octanol partition for neutral
solutes. Plot of the log of the permeability (cm/sec) versus the log
of the octanol/water partition (log D) for the neutral solutes in
Additional file 1: Table 2. The colored points indicate solutes which
may have protein mediated transport: Red = xylose (glucose
transport system); Green = digoxin, β-methyl digoxin and colchicine
(P-glycloprotein mediated efflux); Blue = lamivudine (organic cation
transporter). The solid line is the linear regression fit to the
black points.
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ability. This delay should have a complicated depend-
ence on log D. Solutes with a relatively high log D at
pH 6.5 will be absorbed in the first part of the intestine
and have a correspondingly higher apparent permeability
then solutes with a low log D whose absorption will be
delayed until they reach the pH of 7.4 in the ileum.
Figure 11 shows a plot of log D versus log permeability
for the basic solutes in Additional file 1: Table 2 for a log
D determined at pH 7.4 (Figure 11A), pH 6.4 (Figure 11B)
and pH 5.4 (Figure 11C) using Equation (20) to convert
the log D to the different pHs. The orange point is
midodrine which is a known substrate for the peptide
transport system [46]. The solid line is the linear regres-
sion fit to the black points and the dashed line is the re-
gression for the neutral solutes (Figure 10). The pH 6.4
plot provides the best fit to the neutral solute perme-
ability data (which should not be pH dependent),
suggesting that pH 6.4 is the best average approxima-
tion for basic solutes. This is consistent with the
current recommendation to use a pH of 6.8 for studies
of “simulated” intestinal fluid [34]. As predicted, the
AM permeability of the basic solutes with low log D at
pH 6.4 or 7.4 is less than that of the neutral solutes
(dashed line) because their absorption should be de-
layed until they reach the ileum. This comparisonbetween the neutral and basic solutes is only suggest-
ive because of the small number of neutral solutes in
Additional file 1: Table 2 and their poor correlation
with log D (Figure 10).
The opposite effect should occur for the acidic solutes
which should be absorbed in the proximal (acidic) section
of the intestine. The classic example is aspirin, which has
a pKa of 3.49 and a log D of about −1.8 (average from
LOGKOW) at pH 7.4. From the plots in Figures 10 or 11,
one would predict that a solute with this log D should
have a low permeability of about 0.4 × 10-4 cm/sec,
about 25 times smaller than the experimental AM as-
pirin permeabilities (Additional file 1: Table 2) of 6.69 ×
10-4 cm/sec (Rowland et al. [47] for one subject) or
20.8 × 10-4 cm/sec (Bochner et al. [48], average of 6
subjects). The explanation of this high permeability
has been controversial. Hogben et al. [49] used this
rapid absorption of aspirin to infer that there must be
a pH of about 5.3 at the luminal surface of the epithe-
lial cell maintained by some unknown mechanism
combined with a large unstirred luminal fluid layer.
However, the recognition that the unstirred layer in
humans is only about 35 μm [50] makes this idea unten-
able and direct measurements in guinea pig jejunum do
not find evidence for this acidic mircroclimate [51]. An al-
ternative explanation is that the salicylates are transported
by a monocarboxylic acid carrier system [52,53]. However,
Takagi et al. [54] suggested this result is an artifact
and that pure phospholipid liposomes show the same
apparent “carrier” behavior. The most likely explan-
ation is simply that aspirin is absorbed in the duode-
num and proximal jejunum where the pH varies from
4.4 to 5.4. At a pH of 5.4, the log D of aspirin is about
0.19 (Equation (20)) and small neutral solutes with this
log D (e.g. caffeine, see Figure 10) have high AM per-
meabilities, equal to or greater than are observed for
aspirin. The aspirin permeability at pH 5.4 is presum-
ably high enough that it can be nearly completely
absorbed in this short proximal region.
A dramatic illustration of the effect of this pH hetero-
geneity on the absorption of weak acids is provided by
acetylcysteine which has a pKa of 3.25 and a very low
log D of −2.5 at pH 7.4 with a corresponding log D
of −1.5 at pH 6.4 and −0.6 at pH 5.4. The AM fit to the
blood concentration following the oral dose and the time
course of the intestinal absorption is shown in Figure 4.
Even though the permeability time constant TP is very
fast (6.95 minutes), only about 12% of the 3676 μm oral
dose is absorbed and the absorption stops after about
50 minutes (Figure 4B). This suggests that the absorp-
tion occurred only in the low pH proximal small intes-
tine and this region was cleared by about 50 minutes
after 12% was absorbed and that there was no significant
absorption in the rest of the intestine.
BA
pH = 6.4 
pH = 7.4 
C
pH = 5.4 
Figure 11 Permeability versus octanol partition for basic
solutes. Plot of the log of the permeability (cm/sec) versus the log
of the octanol/water partition (log D) for the basic solutes in
Additional file 1: Table 2. The log D was determined at pH = 7.4
(Figure 11A), 6.4 (Figure 11B) and 5.4 (Figure 11C). The solid line is
the linear regression fit to the black points and the dashed line is
the linear regression fit to the neutral solutes (Figure 10). The orange
point is midodrine which is a substrate for the peptide
transport system.
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the log D at pH 7.4 (Figure 12A), 6.4 (Figure 12B) and
5.4 (Figure 12C) for the 10 acidic solutes in Additional
file 1: Table 2. The solid line is the linear regression fit
to the black points and the dashed line is the regression
for the neutral solutes (Figure 10). There is no signifi-
cant correlation between log D and the permeability.
This is probably because most of these solutes are rela-
tively rapidly and nearly completely absorbed in the
proximal intestine and the log D varies over a smaller
range than the basic solutes (Figure 11).
Figure 13 shows a plot of the log permeability versus
the log D for the 7 solutes in Additional file 1: Table 2
that are charged over the entire pH range 5.4 to 7.4. The
2 green points indicate solutes that may be substrates
for the peptide transport system. All the solutes have
low permeabilities that are less than are predicted by the
neutral solute plot (dashed line). These solutes are prob-
ably absorbed primarily by paracellular transport.
The best currently available measurements of human
small intestinal permeability are the single-pass jejunal
perfusion results of Lennernas and colleagues. Currently,
they have published the jejunal permeability for 28 drugs
[18]. Figure 14 shows a log-log plot of the AM versus
the perfused jejnunal permeability for the 8 drugs that
were studied by both methods. The dashed line is the
line of identity. The black and red points are weak bases
and acids, respectively, and the green point is the un-
charged solute antipyrine. It can be seen that for most
solutes the AM permeability is in good absolute agree-
ment with the direct perfusion permeability - a surprising
result considering the marked differences in experimental
approaches and assumptions for the two methods. The
major exception is the weak acid furosemide (red point)
whose AM permeability (1.54 × 10-4 cm/sec) is 30 times
greater than the perfusion permeability, presumably be-
cause furosemide is absorbed primarily in the proximal je-
junum that has a pH significantly more acid than the pH
of 6.5 used in the perfusion studies.
One can use the AM permeability of the highest
permeability solutes to estimate a lower bound for
the unstirred aqueous layer. For the passively absor-
bed high lipid solubility drugs, the permeability (P)
should be approximately equal to that of the total fluid
CA
B
pH = 5.4 
pH = 6.4 
pH = 7.4 
Figure 12 Permeability versus octanol partition for acidic
solutes. Plot of the log of the permeability (cm/sec) versus the log
of the octanol/water partition (log D) for the acidic solutes in
Additional file 1: Table 2. The log D was determined at pH = 7.4
(Figure 12A), 6.4 (Figure 12B) and 5.4 (Figure 12C). The solid line is
the linear regression fit to the black points and the dashed line is
the linear regression fit to the neutral solutes (Figure 10).
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stirred lumen:
P ¼ DUS=LUS ð21Þ
where LUS is the thickness and DUS is the average diffusion
coefficient for this fluid layer. The small uncharged solutes
(e.g. caffeine, acetaminophen and antipyrine) have the
highest AM permeabilities of about 20 × 10-4 cm/sec
(Additional file 1: Table 2). Assuming a D of 9.1 × 10-6 cm2/
sec for, e.g., antipyrine in water at 37°C [55], L = 45 μm.
Since the epithelial cell thickness is about 25 μm [56], this
corresponds to an unstirred luminal layer of only about
20 μm, similar to the value of 35 μm found by Levitt et al.
[50] for human jejunum. This AM antipyrine permeability
value is about 3 times larger than the value found by
Fagerholm and Lennernas [55] at the highest rates of
jejunal perfusion. The perfusion at a pressure of about
20 mm Hg [57] produces an unphysiological distendedFigure 13 Permeability versus octanol partition for charged
solutes. Plot of the log of the permeability (cm/sec) versus the log
of the octanol/water partition (log D) for the charged solutes in
Additional file 1: Table 2. The solid line is the linear regression fit to
the black points and the dashed line is the linear regression fit to
the neutral solutes (Figure 10). The green points are cefixime and
aztreonam which are substrate for the P-glycloprotein mediated
efflux system.
Figure 14 Comparison of the AM versus the human jejunal
perfusion permeability. Plot of the log of the jejunal permeability
(cm/sec) versus the log of the AM permeabililty (Additional file 1:
Table 2). The dashed line is the line of identity. The red point is the
weak acid furosemide and the green point is the
uncharged antipyrine.
Figure 15 Comparison of the AM versus the Caco-2
permeability. Plot of the log Caco-2 permeability (cm/sec) versus
the log of the AM permeability (Additional file 1: Table 2). The points
are colored on the basis of their charge state: Black = basic, Red =
acidic, Green = uncharged, Blue = charged. The solid line is the
linear regression fit to all the points.
Figure 16 AM fraction absorbed versus AM permeability. Plot of
the AM fraction absorbed versus the log of the AM permeability
(cm/sec). The points are colored on the basis of their charge state:
Black = basic, Red = acidic, Green = uncharged, Blue = charged.
Levitt BMC Pharmacology and Toxicology 2013, 14:34 Page 15 of 17
http://www.biomedcentral.com/2050-6511/14/34jejunum (radius of 1.61 cm) [58] and one might expect
greater unstirred layers than during the nearly fasting
conditions used for the AM studies.
The standard procedure for screening for the intestinal
permeability of drugs is the Caco-2 cell culture system.
Comparison of the AM permeability with the Caco-2
permeability is inexact because of the variety of tech-
niques that have been used for reported Caco-2 values,
with results differing by as much as 10 fold between
different labs [1]. Larregieu and Benet [59] recently
reviewed some of the problems in using Caco-2 as a
surrogate for human permeability measurements.
Thomas et al. [60] recently published a compilation of
results for 120 drugs determined in their lab by the
same method and these values were compared with the
AM values for the drugs studied by both methods
(Additional file 1: Table 2). In addition, Additional
file 1: Table 2 was filled in with Caco-2 results from
other labs. When more than one value was available,
usually the larger permeability was used. Figure 15
shows a log-log plot of the AM versus Caco-2 perme-
ability. The solid line is the linear regression fit. At the
high permeability end of the regression, the AM per-
meability is about 40 times greater than the Caco-2
permeability. This is consistent with a Caco-2 un-
stirred layer that varies, depending on the stirring rate,
from 564 to 2500 μm [61], which is 12 to 55 times
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where the unstirred layer is not limiting, the AM perme-
ability is 6.8 times greater than the Caco-2 permeability.
As discussed in the Background section, the standard
approach for evaluating QSAR predictions of intestinal
drug permeability is to use the human fraction absorbed
as a surrogate for the permeability. Although the limita-
tions of this approach are well recognized [1], it is the
only available correlate of absorption for most drugs.
The plot of the fraction absorbed versus the log of the
AM permeability for the drugs in Additional file 1:
Table 2 (Figure 16) dramatically illustrates this limitation.
For values of the AM P greater than about 10-4 cm/sec,
the drugs are 100% absorbed and, for P less than about
10-5, absorption drops to 10% or less. Thus, although the
permeability varies over a 10,000 fold range, the fraction
absorbed varies from 0.1 to 1 over just a 10 fold perme-
ability range. Although the fraction absorbed is the clinic-
ally most important prediction, it would clearly be useful
to be able predict the permeability over a wider range. The
data in Additional file 1: Table 2 should provide a useful
benchmark for QSAR analysis.
Conclusions
The “averaged model” (AM) model accurately describes
intestinal absorption if the assumptions of the diffusion
convection (DC) model are satisfied. This new simple 3
parameter function (Equation (15)) can be used to deter-
mine by deconvolution the human intestinal permeabil-
ity during the normal human drug absorption process.
The AM permeability is similar to the values measured
using direct jejunal perfusion. Its main limitation results
from the heterogeneity in the small intestinal permeabil-
ity of weak acids and bases produced by the variation in
intestinal pH. Weak acids will tend to be absorbed in
the proximal intestine and weak bases in the terminal in-
testine and this will be represented in the “permeability”
determined by this method. The permeability data for
the 90 drugs described in the Additional file 1: “Table 2”
provides a large data base that should be useful in drug
development and QSAR analysis.
Additional file
Additional file 1: Table 2. Summary of averaged model (AM)
deconvolution analysis of human intestinal absorption. Tabulated summary
of all the permeability data used in the paper “Quantitation of small
intestinal permeability during normal human drug absorption”, D. G. Levitt.
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radius; L: Intestinal length; S: Surface area = 2πrL; V: Volume = πr2L;
N: Number of finite segments in numerical solution; ΔP: PS/N; ΔV: V/N;De: πr2DN/L; Dose: Total oral dose; FA: Fraction of dose absorbed;
IG(t): Convective solute input from stomach; EDC: DC flux from small to large
intestine; ADC(t): DC cumulative amount leaving small intestine; AM:
AM cumulative amount absorbed for case where FA of dose is absorbed;
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